FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023033172> ?p ?o ?g. }

• W2023033172 abstract "Patients undergoing prostate brachytherapy (PB) as monotherapy are often selected on the basis of favorable pretreatment factors. However, intermediate and high-risk prostate cancer patients are commonly offered PB as monotherapy without the addition of external beam radiotherapy (EBRT) or hormonal therapy. This series reports the outcome of patients undergoing PB as monotherapy who were stratified into low, intermediate, and high-risk groups with extended follow-up.A total of 102 patients with clinically localized prostate cancer underwent PB alone as monotherapy. EBRT or hormonal therapy was not part of their initial treatment. Prostate-specific antigen (PSA) relapse-free survival (PRFS) was determined in accordance with the American Society for Therapeutic Radiology and Oncology consensus statement. Patients were stratified as at favorable risk (Stage T1-2a, pretreatment PSA < or =10.0 ng/mL, and Gleason score < or =6), intermediate risk (one prognostic indicator with a higher value), or unfavorable risk (> or =2 indicators with higher values). The median follow-up period for patients in this series was 7 years (range 2.1-9.7). The median age at treatment was 71 years (range 54-80), and the median prescribed dose of (125)I was 145 Gy.Forty patients experienced a biochemical relapse at a median of 1.9 years (range 0.4-4.2). The 5-year actuarial PRFS rate for patients with favorable, intermediate, and unfavorable risk was 85%, 63%, and 24%, respectively (p <0.0001). All but 1 patient had the relapse within the first 5 years of treatment. When stratifying patients on the basis of their pretreatment PSA level, the 5-year PRFS rate for men with a PSA < or =10 ng/mL vs. >10 ng/mL was 78% vs. 35%, respectively (p = 0.0005). Furthermore, the 5-year PRFS rate for men with a Gleason score of < or =6 vs. > or =7 was 74% vs. 33%, respectively (p = 0.0001). No difference was found between Stage T1-T2a and Stage T2b or higher (64% vs. 54%, respectively; p = 0.353).On the basis of risk stratification, PB as monotherapy produces comparable PRFS to EBRT and surgery at 7 years of follow-up. PB as monotherapy is particularly ineffective in patients with unfavorable risk factors, and additional therapy is warranted." @default.
• W2023033172 created "2016-06-24" @default.
• W2023033172 creator A5004217393 @default.
• W2023033172 creator A5052573263 @default.
• W2023033172 creator A5074585611 @default.
• W2023033172 creator A5075165181 @default.
• W2023033172 creator A5087311471 @default.
• W2023033172 creator A5091458648 @default.
• W2023033172 date "2002-07-01" @default.
• W2023033172 modified "2023-09-28" @default.
• W2023033172 title "Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy" @default.
• W2023033172 cites W1868380765 @default.
• W2023033172 cites W1967770117 @default.
• W2023033172 cites W1971949046 @default.
• W2023033172 cites W1979300931 @default.
• W2023033172 cites W1988456256 @default.
• W2023033172 cites W1998002556 @default.
• W2023033172 cites W2002762670 @default.
• W2023033172 cites W2005292676 @default.
• W2023033172 cites W2006743667 @default.
• W2023033172 cites W2007276105 @default.
• W2023033172 cites W2008428383 @default.
• W2023033172 cites W2019569821 @default.
• W2023033172 cites W2026118965 @default.
• W2023033172 cites W2042270713 @default.
• W2023033172 cites W2049153532 @default.
• W2023033172 cites W2054364997 @default.
• W2023033172 cites W2059132676 @default.
• W2023033172 cites W2089403922 @default.
• W2023033172 cites W2093485750 @default.
• W2023033172 cites W2117792530 @default.
• W2023033172 cites W2120328250 @default.
• W2023033172 cites W2122530789 @default.
• W2023033172 cites W2125168442 @default.
• W2023033172 cites W2126645707 @default.
• W2023033172 cites W2129551651 @default.
• W2023033172 cites W2139592406 @default.
• W2023033172 cites W2145201478 @default.
• W2023033172 cites W2148050247 @default.
• W2023033172 cites W2150181583 @default.
• W2023033172 cites W2153314120 @default.
• W2023033172 cites W2329611551 @default.
• W2023033172 cites W2433404723 @default.
• W2023033172 cites W2502134830 @default.
• W2023033172 cites W64310674 @default.
• W2023033172 cites W2069494446 @default.
• W2023033172 cites W2491794389 @default.
• W2023033172 cites W2786428138 @default.
• W2023033172 doi "https://doi.org/10.1016/s0360-3016(02)02796-7" @default.
• W2023033172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12062601" @default.
• W2023033172 hasPublicationYear "2002" @default.
• W2023033172 type Work @default.
• W2023033172 sameAs 2023033172 @default.
• W2023033172 citedByCount "34" @default.
• W2023033172 countsByYear W20230331722012 @default.
• W2023033172 countsByYear W20230331722013 @default.
• W2023033172 countsByYear W20230331722017 @default.
• W2023033172 crossrefType "journal-article" @default.
• W2023033172 hasAuthorship W2023033172A5004217393 @default.
• W2023033172 hasAuthorship W2023033172A5052573263 @default.
• W2023033172 hasAuthorship W2023033172A5074585611 @default.
• W2023033172 hasAuthorship W2023033172A5075165181 @default.
• W2023033172 hasAuthorship W2023033172A5087311471 @default.
• W2023033172 hasAuthorship W2023033172A5091458648 @default.
• W2023033172 hasConcept C121608353 @default.
• W2023033172 hasConcept C126322002 @default.
• W2023033172 hasConcept C126894567 @default.
• W2023033172 hasConcept C143998085 @default.
• W2023033172 hasConcept C146357865 @default.
• W2023033172 hasConcept C151730666 @default.
• W2023033172 hasConcept C2775908122 @default.
• W2023033172 hasConcept C2776235491 @default.
• W2023033172 hasConcept C2777416452 @default.
• W2023033172 hasConcept C2778311097 @default.
• W2023033172 hasConcept C2780192828 @default.
• W2023033172 hasConcept C2781406297 @default.
• W2023033172 hasConcept C509974204 @default.
• W2023033172 hasConcept C71924100 @default.
• W2023033172 hasConcept C86803240 @default.
• W2023033172 hasConceptScore W2023033172C121608353 @default.
• W2023033172 hasConceptScore W2023033172C126322002 @default.
• W2023033172 hasConceptScore W2023033172C126894567 @default.
• W2023033172 hasConceptScore W2023033172C143998085 @default.
• W2023033172 hasConceptScore W2023033172C146357865 @default.
• W2023033172 hasConceptScore W2023033172C151730666 @default.
• W2023033172 hasConceptScore W2023033172C2775908122 @default.
• W2023033172 hasConceptScore W2023033172C2776235491 @default.
• W2023033172 hasConceptScore W2023033172C2777416452 @default.
• W2023033172 hasConceptScore W2023033172C2778311097 @default.
• W2023033172 hasConceptScore W2023033172C2780192828 @default.
• W2023033172 hasConceptScore W2023033172C2781406297 @default.
• W2023033172 hasConceptScore W2023033172C509974204 @default.
• W2023033172 hasConceptScore W2023033172C71924100 @default.
• W2023033172 hasConceptScore W2023033172C86803240 @default.
• W2023033172 hasLocation W20230331721 @default.
• W2023033172 hasLocation W20230331722 @default.
• W2023033172 hasOpenAccess W2023033172 @default.
• W2023033172 hasPrimaryLocation W20230331721 @default.
• W2023033172 hasRelatedWork W1975096840 @default.
• W2023033172 hasRelatedWork W1979803485 @default.

• next